Showing results (21-30 of 41) with videos related to
Sort By:
Pageof 5
Nature Medicine|August 24, 2004
Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasisTatiana V Petrova, Terhi Karpanen, Camilla Norrmén, et al.Journal of Health Services Research & Policy|December 5, 2014
A qualitative study of systemic influences on paramedic decision making: care transitions and patient safetyRachel O'Hara, Maxine Johnson, A Niroshan Siriwardena, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 8, 2010
Randomised phase II trial of hyperbaric oxygen therapy in patients with chronic arm lymphoedema after radiotherapy for cancerLone Gothard, Joanne Haviland, Phil Bryson, et al.JCO Precision Oncology|September 16, 2021
Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)Haider Mahdi, Navid Hafez, Deborah Doroshow, et al.Phlebology|March 8, 2022
The American Venous Forum, American Vein and Lymphatic Society and the Society for Vascular Medicine expert opinion consensus on lymphedema diagnosis and treatmentFedor Lurie, Rafael D Malgor, Teresa Carman, et al.Bioresource Technology|August 23, 2025
Elucidation of the biodegradation pathways of polyurethane and polyethylene terephthalate by a Fusarium strain enriched from soil-plant systemsEyalira Jacob Okal, Yanfei Wu, Shahid Iqbal, et al.European Journal of Cancer (Oxford, England : 1990)|September 20, 2021
First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trialRaphael J Morscher, Caroline Brard, Pablo Berlanga, et al.Cancer|March 11, 2026
Targeted therapy for DNA damage response and homologous recombination repair defects: The Olaparib Combinations trialDeborah B Doroshow, Geoffrey I Shapiro, Khanh Do, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2007
Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanomaMalcolm Ranson, Peter Hersey, Damien Thompson, et al.The New England Journal of Medicine|June 26, 2009
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriersPeter C Fong, David S Boss, Timothy A Yap, et al.Pageof 5